PathoCare Holdings, Inc.—the parent company of medical diagnostics innovator PathoCare, LLC (a leader in the Lab-on-a-Chip non-invasive Point of Care diagnostics)—has developed a set of tests backed by a revolutionary Raman spectroscopy-based testing platform that is underpinned by 17 patents and adaptive AI. Today, the company announced that it has accepted a third-party tender offer involving the secondary purchase of shares from an early investor. While specific transaction details remain undisclosed, the agreement reflects a company valuation of $500 million.
The $500 million valuation assigned to PathoCare Holdings, Inc. in connection with the tender offer was independently determined by Lehrer Financial (a nationally recognized economic and financial consulting firm based in Houston, Texas, with over forty years of experience providing high-precision business valuations). Lehrer Financial has built a reputation for analytical rigor and defensible methodologies across industries—including healthcare, banking, real estate, and emerging technologies.
The transaction was structured in response to shareholder interest in early liquidity and estate planning, and was designed to support the evolving needs of long-term investors. A private institutional investor acquired a portion of PathoCare Holdings’ outstanding equity in a tender offer authorized by the company’s board of directors.
“This tender offer reflects continued confidence in the long-term value and market potential of PathoCare’s breakthrough diagnostics platform,” said L. Mychal Jefferson, Chairman of PathoCare Holdings. “As we scale our technology, we remain committed to supporting the needs of our investors, while enabling mission-critical product development.”
In parallel with the tender offer, PathoCare Holdings is reviewing opening a new private equity financing round to raise up to $25 million from qualified institutional investors. The capital will be used to accelerate the development, engineering, and regulatory readiness of the company’s flagship product—the PathoWand, a next-generation point-of-care diagnostic device utilizing Raman spectroscopy and artificial intelligence for real-time pathogen detection.
This initiative follows a prior $150 million venture investment, acquisition and recapitalization led by Hamershlag Private Capital Management Limited, that resulted in Hamershlag Private acquiring seventy percent (70%) and the original founders receiving thirty percent (30%) of the of the newly restructured and recapitalized company. This marks another major milestone in PathoCare’s transformation from a research-stage venture to a commercial healthcare technology platform.
Lehrer Financial specializes in non-public company valuations, intellectual property analysis, and merger & acquisition consulting, with expertise extending into litigation support and medical economics. Their valuation process included a comprehensive review of PathoCare’s intellectual property portfolio, operating models, industry forecasts, and growth trajectory within the diagnostic testing sector.
Lehrer’s valuation is supported by robust market and financial analysis and is designed to meet the highest professional standards—providing a credible foundation for both private equity transactions and shareholder decisions. The firm’s long-standing reputation for producing concise, defensible, and expert-backed assessments ensured that PathoCare’s corporate valuation could stand up to scrutiny from institutional investors and strategic advisors alike.
About PathoCare Holdings, Inc.
PathoCare Holdings, Inc. is the investment and holding entity created to support venture funding and corporate development of PathoCare, LLC. The company oversees strategic partnerships, capital structuring, and growth planning to expand PathoCare’s patented Raman spectroscopy-based diagnostic platform.
About PathoCare, LLC
PathoCare, LLC is a Houston-based diagnostics technology company leveraging Raman spectroscopy and adaptive AI to deliver accurate, programmable, and reusable point-of-care testing systems. Its patented platform enables rapid, non-invasive diagnostics for bacterial and viral respiratory infections without the need for chemical reagents or long lab processing times. The company is a leader in the Lab-on-a-Chip non-invasive Point of Care diagnostic tests. PathoCare’s revolutionary Raman spectroscopy-based testing platform is underpinned by 17 patents.
About Hamershlag Private Capital Management, Limited
Hamershlag Private is a family investment office dedicated to investing in category defining companies and projects across industries and sectors. They provide long term, flexible capital with a unique ability to act quickly on impactful opportunities. They maintain a diversified portfolio, with a focus on disruptive technologies, climate impact, and emerging industries by cultivating extensive long-term relationships with other family offices and investment firms across asset classes. Hamershlag Private combines institutional infrastructure with core values of flexibility, creativity, and execution.
https://www.hamershlagprivate.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250717989740/en/
Contacts
For media inquiries or further information, please contact:
Investor Relations – PathoCare Holdings, Inc.
718-880-8014
info@hamershlagprivate.com
www.spectroscopy.health